OLS OMNI Life Science and Namocell sign distribution agreement

OLS OMNI Life Science announced a distribution agreement with Namocell Inc., a provider of high-performance single cell sorting and dispensing platforms. As of now on OLS OMNI Life Science offers an expanded cell research portfolio focused next to single cell sorting and dispensing on cell culture, counting, flow cytometry, Analysis and Imaging.

“There has been significant demand for our Single Cell Dispensers in Germany and Austria,” said Namocell CEO Dr. Junyu Lin. OLS as a leading player in the Germany and Austria markets with strong track record in distributing cell-based research is a perfect partner to serve the markets.

“Namocell’s industry-leading single cell isolation instruments are a game-changer for cell line engineering and development, CRISPR, single cell genomics, antibody development and other single cell applications. The Namocell Single Cell Dispenser is fast, gentle and very easy to use. It enables researchers to sort and dispense single cells within minutes while preserving cell viability and integrity, so you can get excellent outgrowth and better data. It can handle sample input ranging from 100 cells to 150 million cells/mL. The versatility offers an ideal solution no matter you have precious clinical samples or want to isolate extremely rare cells from a large amount of cells,” said Dr. Andreas Friese, OLS Director Sales & Marketing. “We are very excited to bring these innovative high-performance instruments to more labs in Germany and Austria.”